Clinical manifestations of hydropic ear disease (Menière's)
R Gürkov, C Jerin, W Flatz, R Maxwell - European Archives of Oto-Rhino-Laryngology, 2018
Page 1. Vol.:(0123456789) 1 3 European Archives of Oto-Rhino-
Laryngology https://ift.tt/2ykTTOJ OTOLOGY Clinical
manifestations of hydropic ear disease (Menière's) Robert Gürkov1 …
Laryngology https://ift.tt/2ykTTOJ OTOLOGY Clinical
manifestations of hydropic ear disease (Menière's) Robert Gürkov1 …
[PDF] Perfusion by delayed time to peak in vertebrobasilar dolichoectasia patients with vertigo
YF Peng, HL Zhang, DP Zhang, M Zhao, SL Zhang… - Annals of Clinical and …, 2018
… test. Those with definitive diagnosis of benign paroxysmal positional vertigo (BPPV),
Meniere's Disease, aural vertigo, recurrent ischemic strokes, atrial fibrillation, or
congenital heart disease history were ineligible for inclusion …
Meniere's Disease, aural vertigo, recurrent ischemic strokes, atrial fibrillation, or
congenital heart disease history were ineligible for inclusion …
[PDF] Identification of Ebsulfur Analogues with Broad-Spectrum Antifungal Activity
S Garneau-Tsodikova, HX Ngo, SK Shrestha - US Patent App. 15/940,544, 2018
… biological pathways. Mol. Biol. Rep. 41, 4865-4879). Ebselen is currently in phase
2 clinical trials for the treatment of chemotherapy-induced hearing loss and Meniere's
disease (https://ift.tt/KkipBP). Furthermore, ebselen …
2 clinical trials for the treatment of chemotherapy-induced hearing loss and Meniere's
disease (https://ift.tt/KkipBP). Furthermore, ebselen …
Technological Evolution of Thin-film Solar Cells through Main Path Analysis
V Kumar, HC Chen, CY Lin, KK Lai, YH Chang - … on E-Society, E-Education and E …, 2018
… Patent portfolios and knowledge flow(s) of photovoltaic companies.
Technology Analysis & Strategic Management, 1-18. [4] de la Tour, A.,
Glachant, M., & Meniere, Y. (2011). Innovation and international technology …
Technology Analysis & Strategic Management, 1-18. [4] de la Tour, A.,
Glachant, M., & Meniere, Y. (2011). Innovation and international technology …
[PDF] Phosphorylcholine conjugates and uses thereof
Y Shoenfeld, M Blank - US Patent App. 15/991,335, 2018
… diabetes (Type 1 diabetes), juvenile myositis, Kawasaki syndrome,
Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen
sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), Lupus (SLE) …
Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen
sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), Lupus (SLE) …
[PDF] Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing …
S Uramatsu, T Uemura, M MORIZANE, T Shimamoto - US Patent App. 15/765,808, 2018
US20180280304A1 - Composite granulated product including sugar or sugar alcohol,
swelling binder, disintegrating agent and highly absorbent excipient, and method for
manufacturing composite granulated product - Google Patents …
swelling binder, disintegrating agent and highly absorbent excipient, and method for
manufacturing composite granulated product - Google Patents …
[PDF] A retrospective analysis of haemotologic parameters in patients with bilateral tinnitus
U Düzenli, N Bozan, M Aslan, H Özkan, M Turan… - Age
… However, there are not any certain pathophysiological explanations about tinnitus
(15- 17). This clinical problem can occur at older ages and decrease hearing caused
by any ear diseases like otosclerosis, Meniere etc. noise …
(15- 17). This clinical problem can occur at older ages and decrease hearing caused
by any ear diseases like otosclerosis, Meniere etc. noise …
[PDF] Schwindel: Wir wissen zu wenig und schwindeln zu viel darüber
S Hegemann
… DOI: https://ift.tt/2ykUxM9 6. Adrion C, Fischer CS, Wagner
J, Gürkov R, Mansmann U, Strupp M: Ef- ficacy and safety of betahistine
treatment in patients with Meniere's disease: primary results of a long term …
J, Gürkov R, Mansmann U, Strupp M: Ef- ficacy and safety of betahistine
treatment in patients with Meniere's disease: primary results of a long term …
[PDF] Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
A Sicard, O Thaunat - US Patent App. 15/763,566, 2018
US20180280536A1 - Biofunctionalized nanoparticles and uses thereof in adoptive
cell therapy - Google Patents. Biofunctionalized nanoparticles and uses thereof in
adoptive cell therapy. Download PDF Info. Publication number …
cell therapy - Google Patents. Biofunctionalized nanoparticles and uses thereof in
adoptive cell therapy. Download PDF Info. Publication number …
[PDF] Use of flaxseed and flaxseed derivatives for treatment of neurological disorders and viral diseases
M Christofidou-Solomidou, K JORDAN-SCIUTTO - US Patent App. 15/995,128, 2018
US20180280462A1 - Use of flaxseed and flaxseed derivatives for treatment of neurological
disorders and viral diseases - Google Patents. Use of flaxseed and flaxseed derivatives
for treatment of neurological disorders and viral diseases. Download PDF Info …
disorders and viral diseases - Google Patents. Use of flaxseed and flaxseed derivatives
for treatment of neurological disorders and viral diseases. Download PDF Info …
Αυτή η ειδοποίηση αποστέλλεται από τον Μελετητή Google. Ο Μελετητής Google είναι μια υπηρεσία που παρέχεται από την Google.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου